Cantor Fitzgerald upgraded Supernus (SUPN) to Overweight from Neutral with a price target of $42, up from $36.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus announces expiration of HSR waiting period for Sage Therapeutics
- Sage Therapeutics cutting over 330 jobs, Boston Globe reports
- Supernus Pharmaceuticals Holds Annual Stockholders Meeting
- H.C. Wainwright sees potential competition for Sage from Biogen
- Sage Therapeutics price target raised to $9 from $8 at Truist